Why is Medicamen Biotec falling/rising?

As of 07-Jul, Medicamen Biotech Ltd is currently priced at 402.75, reflecting a slight increase of 0.75 (0.19%). Despite this minor uptick, the stock has shown a significant decline over the past month, with a return of -5.56%, and a year-to-date drop of -20.91%. The stock is trading below its moving averages across all time frames, indicating a bearish trend. However, there has been a notable increase in investor participation, with delivery volume rising by 38.81% compared to the 5-day average. The company maintains a low Debt to Equity ratio, but its long-term growth prospects are concerning, as evidenced by a -16.39% annual decline in operating profit over the last five years and a low return on capital employed (ROCE) of 5.30%.
In the broader market context, the Sensex has shown a positive return of +1.53% over the past month, contrasting sharply with Medicamen's performance. The stock has consistently underperformed against the benchmark, generating a return of -19.97% over the past year while the Sensex has gained +4.31%. This consistent underperformance, coupled with declining profits and low cash reserves, suggests that investor sentiment remains cautious regarding Medicamen Biotech's future growth potential.